CD274 and non-small cell lung carcinoma: Two randomized, phase III studies, comparing Nivolumab vs docetaxel, in pre-treated, both squamous [23] and non-squamous [24] NSCLC patients, have both shown a significant improvement of the ORR and OS in the overall population treated with Nivolumab, reporting opposite results in the PD-L1 expression analysis.